Evidence map›Paper›PMID 40644440›Full record

ArticlePloS one2025

Herd immunity and prevention in HPV transmission with exogenous reinfection.

Md Mehedi Hasan, Md Hamidul Islam

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Md Mehedi HasanDepartment of Applied Mathematics, University of Rajshahi, Rajshahi, Bangladesh.
Md Hamidul IslamDepartment of Applied Mathematics, University of Rajshahi, Rajshahi, Bangladesh.ORCID https://orcid.org/0000-0003-3258-0700

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cervical cancer is a major global health concern, primarily caused by human papillomavirus (HPV), which spreads through unsafe sexual contact. Natural immunity often fails to provide full protection, permitting exogenous reinfection, which plays a key role in the persistence and transmission of HPV. This paper presents and analyzes a deterministic mathematical model of HPV transmission, incorporating exogenous re-infection. We utilized VIA test result data from 2019 to 2023 in Bangladesh to estimate key parameter values. The findings were validated through numerical simulations using MATLAB, and the analytical results demonstrated strong consistency with the numerical outputs. A critical insight is the presence of reinfection-induced backward bifurcation, indicating that targeting primary infections alone is insufficient for eradication, highlighting the need to address exogenous reinfection for effective control. We propose optimal control strategies tailored to resource-limited settings like Bangladesh, where limited vaccine access presents significant challenges, and community-driven education on safe sexual practices is crucial and continuously evolving. The results emphasize that the most effective approach combines targeted prevention with widespread community education, while precision in intervention implementation is essential to prevent reinfection surges that could prolong disease persistence and undermine control efforts. These insights provide a strong foundation for refining intervention strategies and offer valuable guidance for controlling HPV transmission through non-pharmaceutical interventions, particularly in resource-constrained settings.

Indexed as

Immunity, HerdPapillomaviridaePapillomavirus InfectionsReinfectionUterine Cervical NeoplasmsBangladeshFemaleHumansModels, TheoreticalPapillomavirus VaccinesPapillomavirus Vaccines

Identifiers

PMID40644440
PMCPMC12250543

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.